Press release - 06/10/2026 EXIST funding for xenko start-up team at Ulm University Virtual health platform to encourage more physical activity in the working day The start-up xenko has been awarded an EXIST grant of 143,500 € from the Federal Ministry for Economic Affairs and Energy. The team of founders from Ulm University is developing a digital health platform designed to encourage more physical activity in everyday working life through virtual reality. This development is of interest to companies with occupational health management schemes and, in the long term, to the physiotherapy sector as well.https://www.gesundheitsindustrie-bw.de/en/article/press-release/exist-funding-xenko-start-team-ulm-university-virtual-health-platform-encourage-more-physical-activity-working-day
Press release - 24/09/2026 Enzyme Beads for More Sustainable Chemistry Thanks to enzyme-based biocatalysis, an enormous range of pharmaceutical active ingredients and other complex molecules can be synthesized in an environmentally friendly manner. Researchers at the Karlsruhe Institute of Technology (KIT) have now developed a technology that allows to assemble enzymes into millimeter-sized, storable beads. In this process, the enzymes not only act as catalysts but also constitute the beads’ material itself.https://www.gesundheitsindustrie-bw.de/en/article/press-release/enzyme-beads-more-sustainable-chemistry
Event - 13/04/2027 - 15/04/2027 DMEA 2027 Munich, Fair https://www.gesundheitsindustrie-bw.de/en/event/dmea-2027-en
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer
Event - 13/05/2027 - 15/05/2027 REHAB 2027 Karlsruhe, fair https://www.gesundheitsindustrie-bw.de/en/event/rehab-2027-en
Press release - 05/10/2026 How blood flow controls liver function The liver is organized into distinct zones in which liver cells perform different functions. The blood vessels of the liver play an important role in this spatial organization: the endothelial cells lining the vessels provide signals that instruct neighboring liver cells and help determine their function. But how do endothelial cells know which signals to produce?https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-flow-controls-liver-function
Press release - 06/10/2026 Harnessing Synthetic Cellular Systems as Immune Cell Boosters How can cell-based immunotherapies for cancer and autoimmune diseases become more widely available in the long term? The SYNTHIA project is addressing this challenge: The Max Planck Institute for Medical Research and the Fraunhofer Institute for Cell Therapy and Immunology IZI are collaborating on new research approaches to advance the development of cell-based immunotherapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/harnessing-synthetic-cellular-systems-immune-cell-boosters
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer-1
Press release - 08/10/2026 High iron levels may promote the mobility of brain tumor cells Iron is essential for healthy cells. Cancer cells also require this trace element. Researchers in Freiburg have now found evidence that high levels of iron directly in the tumor microenvironment promote the spread of certain cells in a particularly aggressive type of brain tumor known as glioblastoma. In the long term, iron metabolism could therefore serve as a target for more precisely influencing particularly invasive tumor cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-iron-levels-may-promote-mobility-brain-tumor-cells
Event - 18/11/2026 Match Arena Stuttgart, Networking Event https://www.gesundheitsindustrie-bw.de/en/event/match-arena-en
Press release - 16/10/2026 Epilepsy: AI Aims to Improve Treatment with Brain Pacemakers About 250,000 people in Germany live with epilepsy that does not respond adequately to medication. How can their treatment be further improved with a brain pacemaker? As part of the CLOUDIA research project, the Medical Center – University of Freiburg is now collaborating with a medical technology company to develop an AI-supported assistance system for analyzing long-term brain activity data.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epilepsy-ai-aims-improve-treatment-brain-pacemakers
Prime Vector Technologies is developing a new vaccine platform - 20/10/2026 The ORF platform – one virus, many possibilities Many vaccines effectively deliver an antigen to the desired target site. But what if, at the same time, the immune system could be specifically orchestrated to build broad and comprehensive protection? This idea led to the development of a novel vector platform based on the Orf virus. The work was carried out by the Tübingen-based start-up Prime Vector Technologies.https://www.gesundheitsindustrie-bw.de/en/article/news/orf-platform-one-virus-many-possibilities
Press release - 15/10/2026 Four Million Euros in EU Funding to Improve Prostate Cancer Care A European research consortium led by the German Cancer Research Center (DKFZ) aims to fundamentally improve the diagnosis and treatment of prostate cancer using AI agents, big data, and patient-centered clinical decision support. The central goal is to detect aggressive tumors early and accurately, reduce unnecessary interventions, and tailor treatment decisions more closely to the individual patient.https://www.gesundheitsindustrie-bw.de/en/article/press-release/four-million-euros-eu-funding-improve-prostate-cancer-care
Press release - 16/10/2026 A new approach to osteoporosis treatment Disabling a bone formation inhibiting protein molecule How can the human body be stimulated to build more bone, thus helping those affected by osteoporosis? Researchers in Ulm have investigated the role played by the protein molecule Axl in this process. Their efforts were successful: in a study, they demonstrated that Axl inhibits bone formation – and that cells produce significantly more bone tissue when the molecule is blocked using medication. There are no discernible harmful side effects. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-osteoporosis-treatment-disabling-bone-formation-inhibiting-protein-molecule
Funding GeneNovate | Call for Application 2027 Funding programme, Funded by: Federal Ministry of Research, Technology and Space, sb_search.searchresult.label.programSubmissionDate: 13/11/2026 https://www.gesundheitsindustrie-bw.de/en/database/funding/genenovate-call-application-20252026
Press release - 19/10/2026 New Biotech Master’s Degree Launches at Ulm University: Pharmaceutical and Molecular Biotechnology How do RNA-, protein- or stem cell-based therapies work? How can data science methods from bioinformatics and artificial intelligence be used to develop new pharmaceutical active substances? Students at Ulm University are learning this in the new master’s programme in Pharmaceutical and Molecular Biotechnology (PMB).https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-biotech-masters-degree-launches-ulm-university-pharmaceutical-and-molecular-biotechnology
Event - 04/11/2026 Lunch & Learn ahead of MEDICA: Collaborative R&D funding for healthcare innovation in UK and Germany Online (Webex), Registration deadline: 02/11/2026, information event https://www.gesundheitsindustrie-bw.de/en/event/lunch-und-learn-ahead-medica-collaborative-r-und-d-funding-healthcare-innovation-uk-and-germany
Robotics in medicine: initial trials of HASEL technology - 04/11/2026 Using artificial muscles to reduce uncontrolled tremors For people with tremors, even simple everyday tasks can become a challenge. Researchers from Stuttgart and Tübingen are developing a novel assistive system designed to actively suppress these involuntary movements. Initial tests using artificial muscles based on HASEL technology have shown promising results – but there is still a long way to go before the technology is ready for everyday use.https://www.gesundheitsindustrie-bw.de/en/article/news/using-artificial-muscles-reduce-uncontrolled-tremors
Press release - 29/10/2026 VUSE XR closes €1.2 million pre-seed round to scale enterprise mixed reality training VUSE XR today announced the closing of a €1.2 million pre-seed financing round led by IACD, a Düsseldorf-based business angel network. The company develops the VUSE XR Hub, an enterprise software solution for creating and deploying mixed reality training for industrial and life sciences companies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vuse-xr-closes-euro-12-million-pre-seed-round-scale-enterprise-mixed-reality-training
Press release - 29/10/2026 New Approach Could Make Immunotherapy for Blood Cancer More Precise Researchers at the Faculty of Medicine – University of Freiburg have developed a new approach to specifically target an aggressive form of blood cancer while better sparing healthy immune cells. In what is known as T-cell acute lymphoblastic leukemia (T-ALL), cancer cells develop from the body’s own immune defense cells. This complicates treatment, as immunotherapies studied to date can also destroy healthy immune cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-could-make-immunotherapy-blood-cancer-more-precise
Press release - 20/10/2026 How randomness makes artificial vision more reliable Humans are usually remarkably good at recognising objects, even under poor viewing conditions. Artificial vision systems, by contrast, reach their limits more quickly when images are distorted or unfamiliar. Researchers at the Hertie Institute for Clinical Brain Research (HIH) have now investigated what artificial vision systems can learn from the brain.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-randomness-makes-artificial-vision-more-reliable
Press release - 26/10/2026 Multiple sclerosis: New treatment significantly reduces relapses A new treatment could improve care for people with relapsing multiple sclerosis (MS). In two international studies involving a total of 2,007 patients, remibrutinib reduced the annualized relapse rate by 31% to 35% compared with an established MS therapy. New inflammatory brain lesions were also significantly less frequent. In addition, there are indications that the treatment may slow the progression of physical disability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multiple-sclerosis-new-treatment-significantly-reduces-relapses
Press release - 04/11/2026 Molecular guardian inhibits aggressive brain tumor's ability to switch between identities One of the reasons for the high aggressiveness of glioblastomas is their remarkable adaptability. A team led by scientists from the German Cancer Research Center (DKFZ), the EMBL, HITBR*, and the Wellcome Sanger Institute, Cambridge, now describes how glioblastoma cells switch between different states. At the same time, they identified a key factor that, acting as a guardian of cell identity, limits this adaptability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-guardian-inhibits-aggressive-brain-tumors-ability-switch-between-identities
Event - 18/11/2026 BW-UK networking evening at MEDICA 2026 Baden-Württemberg joint booth G24 in hall 15, trade-fair MEDICA, Registration deadline: 16/11/2026, Messe https://www.gesundheitsindustrie-bw.de/en/event/bw-uk-networking-evening-medica-2026